LIVE NOW:Watch the Definedge Conference on Market Analysis (DECMA). Join Now
you are here: HomeNewsBusiness

USFDA ‘closes' warning letter for three sites of Dr Reddy's Laboratories

In November 2015, the company said it had received a warning letter from the US Food and Drug Administration (USFDA) for three of its sites -- active pharmaceutical ingredient (API) manufacturing facilities at Srikakulum, Andhra Pradesh, and Miryalguda, Telengana, and Oncology formulation manufacturing facility at Duvadda, Visakhapatnam, Andhra Pradesh.

August 28, 2020 / 01:06 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Dr Reddy's Laboratories on Friday said the US health regulator Food has “closed” warning letter issued for three of its sites in Andhra Pradesh and Telangana, following evaluation of corrective actions taken by the company.

In November 2015, the company said it had received a warning letter from the US Food and Drug Administration (USFDA) for three of its sites -- active pharmaceutical ingredient (API) manufacturing facilities at Srikakulum, Andhra Pradesh, and Miryalguda, Telengana, and Oncology formulation manufacturing facility at Duvadda, Visakhapatnam, Andhra Pradesh.

"...We have now been informed by the USFDA that based on its evaluation, we have addressed the violations and deviations contained in the said warning letter. With this, the said warning letter has been closed," Dr Reddy's Laboratories said in a regulatory filing.

Shares of Dr Reddy's Laboratories were trading 0.60 percent lower at Rs 4,411.30 apiece on the BSE.
PTI
first published: Aug 28, 2020 12:50 pm

stay updated

Get Daily News on your Browser
Sections